http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 07 Jul 2026 17:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jul+06++Filed+by%3A+Michaelson+Jennifer/26742532.html si-local-file:///var/storage/secattach/20260707/26742532.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jul+06++Filed+by%3A+Michaelson+Jennifer/26742532.html Tue, 07 Jul 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jul+06++Filed+by%3A+Michaelson+Jennifer/26742532.html si-local-file:///var/storage/secattach/20260707/26742532.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jul+06++Filed+by%3A+Michaelson+Jennifer/26742532.html Tue, 07 Jul 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Fenton+Mary+Kay/26729197.html si-local-file:///var/storage/secattach/20260702/26729197.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Fenton+Mary+Kay/26729197.html Thu, 02 Jul 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Fenton+Mary+Kay/26729197.html si-local-file:///var/storage/secattach/20260702/26729197.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+Fenton+Mary+Kay/26729197.html Thu, 02 Jul 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+SUMER+JACQUELYN+L/26729217.html si-local-file:///var/storage/secattach/20260702/26729217.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+SUMER+JACQUELYN+L/26729217.html Thu, 02 Jul 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+SUMER+JACQUELYN+L/26729217.html si-local-file:///var/storage/secattach/20260702/26729217.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+30++Filed+by%3A+SUMER+JACQUELYN+L/26729217.html Thu, 02 Jul 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Allen+Andrew+R/26667063.html si-local-file:///var/storage/secattach/20260618/26667063.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Allen+Andrew+R/26667063.html Thu, 18 Jun 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Allen+Andrew+R/26667063.html si-local-file:///var/storage/secattach/20260618/26667063.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Allen+Andrew+R/26667063.html Thu, 18 Jun 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Rosenberg+Anthony/26667068.html si-local-file:///var/storage/secattach/20260618/26667068.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Rosenberg+Anthony/26667068.html Thu, 18 Jun 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Rosenberg+Anthony/26667068.html si-local-file:///var/storage/secattach/20260618/26667068.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Rosenberg+Anthony/26667068.html Thu, 18 Jun 2026 17:01:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Doyle+Mittie/26667040.html si-local-file:///var/storage/secattach/20260618/26667040.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Doyle+Mittie/26667040.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Doyle+Mittie/26667040.html si-local-file:///var/storage/secattach/20260618/26667040.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Doyle+Mittie/26667040.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Thistle+Mary/26667049.html si-local-file:///var/storage/secattach/20260618/26667049.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Thistle+Mary/26667049.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Thistle+Mary/26667049.html si-local-file:///var/storage/secattach/20260618/26667049.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Thistle+Mary/26667049.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Webster+Stephen+W/26667056.html si-local-file:///var/storage/secattach/20260618/26667056.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Webster+Stephen+W/26667056.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Webster+Stephen+W/26667056.html si-local-file:///var/storage/secattach/20260618/26667056.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Webster+Stephen+W/26667056.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Meek+David+D./26667060.html si-local-file:///var/storage/secattach/20260618/26667060.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Meek+David+D./26667060.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Meek+David+D./26667060.html si-local-file:///var/storage/secattach/20260618/26667060.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cullinan+Therapeutics%2C++++For%3A+Jun+16++Filed+by%3A+Meek+David+D./26667060.html Thu, 18 Jun 2026 17:00:00 -0400 CGEM O.49467714 http://www.streetinsider.com/Analyst+Comments/William+Blair+on+Cullinan+Oncology+Inc.+%28CGEM%29%3A+%27We+continue+to+see+multiple+opportunities+for+upside+to+Cullinan+shares%27/26630041.html <p>William Blair analyst Matt Phipps reiterated an Outperform rating on Cullinan Oncology Inc. (NASDAQ: CGEM).</p><p>The analyst comments "On Wednesday, June 10, Cullinan hosted an Immunology Day event in New York City. Management presented additional data points from the Phase I trials of CLN-978 (CD19 x CD3 TCE) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) following initial results recently presented at EULAR (see our note), including first efficacy data from repeat-dosing cohorts in the RA study and first safety data from the repeat-dosing cohorts in the SLE study. Management also disclosed initial data for velinotamig (BCMA x CD3 TCE, http://www.streetinsider.com/Analyst+Comments/William+Blair+on+Cullinan+Oncology+Inc.+%28CGEM%29%3A+%27We+continue+to+see+multiple+opportunities+for+upside+to+Cullinan+shares%27/26630041.html Wed, 10 Jun 2026 16:14:57 -0400 CGEM http://www.streetinsider.com/Analyst+PT+Change/Cullinan+Oncology+Inc.+%28CGEM%29+PT+Raised+to+%2446+at+Clear+Street/26629957.html Clear Street analyst Kaveri Pohlman raised the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $46.00 (from $33.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Cullinan+Oncology+Inc.+%28CGEM%29+PT+Raised+to+%2446+at+Clear+Street/26629957.html Wed, 10 Jun 2026 16:10:17 -0400 CGEM http://www.streetinsider.com/Corporate+News/Cullinan+Therapeutics+reports+clinical+trial+data+for+autoimmune+treatments/26626566.html <p>Cullinan Therapeutics Inc. (NASDAQ: CGEM) reported clinical data for two T cell engager therapies targeting autoimmune diseases. The Cambridge, Massachusetts-based biopharmaceutical company presented results from ongoing Phase 1 trials of CLN-978 for rheumatoid arthritis and systemic lupus erythematosus, and initial data for velinotamig in lupus patients.</p><p>In the OUTRACE rheumatoid arthritis trial, CLN-978 achieved clinical remission in one heavily pre-treated patient who had been refractory to rituximab. The patient's DAS28-ESR disease score decreased from 4.0 at baseline to 2.2 at week 4, maintained through week 8. The treatment was associated with rapid reduction in rheumatoid arthritis-related autoantibodies.</p><p>For systemic lupus erythematosus patients http://www.streetinsider.com/Corporate+News/Cullinan+Therapeutics+reports+clinical+trial+data+for+autoimmune+treatments/26626566.html Wed, 10 Jun 2026 07:30:34 -0400 CGEM http://www.streetinsider.com/FDA/Cullinan+Therapeutics+reports+clinical+trial+data+for+autoimmune+treatments/26626566.html <p>Cullinan Therapeutics Inc. (NASDAQ: CGEM) reported clinical data for two T cell engager therapies targeting autoimmune diseases. The Cambridge, Massachusetts-based biopharmaceutical company presented results from ongoing Phase 1 trials of CLN-978 for rheumatoid arthritis and systemic lupus erythematosus, and initial data for velinotamig in lupus patients.</p><p>In the OUTRACE rheumatoid arthritis trial, CLN-978 achieved clinical remission in one heavily pre-treated patient who had been refractory to rituximab. The patient's DAS28-ESR disease score decreased from 4.0 at baseline to 2.2 at week 4, maintained through week 8. The treatment was associated with rapid reduction in rheumatoid arthritis-related autoantibodies.</p><p>For systemic lupus erythematosus patients http://www.streetinsider.com/FDA/Cullinan+Therapeutics+reports+clinical+trial+data+for+autoimmune+treatments/26626566.html Wed, 10 Jun 2026 07:30:34 -0400 CGEM http://www.streetinsider.com/Press+Releases/Cullinan+Therapeutics+Shares+New+Clinical+Data+Across+Its+Portfolio+of+T+Cell+Engager+Programs+Targeting+CD19+and+BCMA+in+Autoimmune+Diseases/26626545.html <p align="center"><em>CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)</em></p> <p align="center"><em>CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile</em></p> <p align="center"><em>Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases</em></p> <p align="center"><em>Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases </em></p> <p align="center"><em>Management to host Immunology Day event http://www.streetinsider.com/Press+Releases/Cullinan+Therapeutics+Shares+New+Clinical+Data+Across+Its+Portfolio+of+T+Cell+Engager+Programs+Targeting+CD19+and+BCMA+in+Autoimmune+Diseases/26626545.html Wed, 10 Jun 2026 07:30:00 -0400 CGEM CGEM http://www.streetinsider.com/Press+Releases/Cullinan+Therapeutics+Shares+New+Clinical+Data+Across+Its+Portfolio+of+T+Cell+Engager+Programs+Targeting+CD19+and+BCMA+in+Autoimmune+Diseases/26626545.html <p align="center"><em>CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)</em></p> <p align="center"><em>CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile</em></p> <p align="center"><em>Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases</em></p> <p align="center"><em>Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases </em></p> <p align="center"><em>Management to host Immunology Day event http://www.streetinsider.com/Press+Releases/Cullinan+Therapeutics+Shares+New+Clinical+Data+Across+Its+Portfolio+of+T+Cell+Engager+Programs+Targeting+CD19+and+BCMA+in+Autoimmune+Diseases/26626545.html Wed, 10 Jun 2026 07:30:00 -0400 CGEM CGEM http://www.streetinsider.com/Globe+Newswire/Cullinan+Therapeutics+Shares+New+Clinical+Data+Across+Its+Portfolio+of+T+Cell+Engager+Programs+Targeting+CD19+and+BCMA+in+Autoimmune+Diseases/26626545.html <p align="center"><em>CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)</em></p> <p align="center"><em>CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a poly-refractory patient, with a favorable safety profile</em></p> <p align="center"><em>Initial velinotamig (BCMA TCE) data show promising clinical activity, including complete renal responses in lupus nephritis, supporting potential in plasma cell–driven autoimmune diseases</em></p> <p align="center"><em>Complementary T cell engager portfolio unlocks broad commercial opportunity across B cell–driven and autoantibody-mediated diseases </em></p> <p align="center"><em>Management to host Immunology Day event http://www.streetinsider.com/Globe+Newswire/Cullinan+Therapeutics+Shares+New+Clinical+Data+Across+Its+Portfolio+of+T+Cell+Engager+Programs+Targeting+CD19+and+BCMA+in+Autoimmune+Diseases/26626545.html Wed, 10 Jun 2026 07:30:00 -0400 CGEM CGEM